Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Abilita GPRC5D small molecule-ADC
- Development stage
- Preclinical
- Lead developer
- Abilita Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Abilita Therapeutics is developing a GPRC5D-targeted therapeutic for the treatment of multiple myeloma, currently in the discovery stage. This program, identified as GPRC5D program #3 in the company's pipeline, utilizes Abilita's proprietary EMP™ (Enhanced Membrane Protein) platform to target G protein-coupled receptor class C group 5 member D (GPRC5D), an orphan GPCR that is highly and specifically expressed on the surface of malignant plasma cells. The program explores both small molecule and antibody-drug conjugate (ADC) modalities—potentially as a small molecule-drug conjugate (SMDC)—to deliver potent cytotoxic payloads specifically to myeloma cells while minimizing off-target effects. The EMP™ technology enables the production of stabilized, correctly folded GPCRs to facilitate the discovery of high-affinity ligands against challenging membrane protein targets.
- Other names
- Abilita GPRC5D SMDC
02
Targets
GPRC5D
Beyond the preview
Go deeper on Abilita GPRC5D small molecule-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abilita GPRC5D small molecule-ADC.